Detecting liver scarring in chronic liver disease
Part of Digestive system clinical trials.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a chronic (long-term) liver condition caused by alcohol, fatty liver, viruses, autoimmune issues, blocked bile ducts, or iron overload.
- You cannot have acute (sudden) hepatitis.
- You must be able to safely have a Fibroscan (a special ultrasound for the liver). This means you cannot have fluid in the belly (ascites) or severe heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
This study is for people with type 2 diabetes who may have early liver damage (fatty liver) but haven't yet developed severe scarring. It tests a simple screening program to find advanced liver fibrosis early, so it can be treated sooner.
This study enrolls people with confirmed fatty liver to help researchers create and validate tests that may estimate liver scarring (fibrosis). It focuses on collecting medical information and verifying the liver condition using lab/scan results, which could help improve future care.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study looks at whether simple blood tests can help predict liver scarring (fibrosis) in people with fatty liver disease. If you join, you'll have a quick, non-invasive scan of your liver to check for fat and scarring.
Hear when a new Chronic Liver Disease (CLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.